Personalized HIV therapy to control drug resistance

Lengauer, 2012, Bioinformatical assistance of selecting anti-HIV therapies: where do we stand?, Intervirology, 55, 108, 10.1159/000332000 Walter, 1999, Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors, J Clin Virol, 13, 71, 10.1016/S1386-6532(99)00010-4 Lengauer, 2006, Bioinformatics-assisted anti-HIV therapy, Nat Rev Microbiol, 4, 790, 10.1038/nrmicro1477 Johnson, 2013, Update of the drug resistance mutations in HIV-1: March 2013, Top Antivir Med, 21, 6 Durant, 1999, Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial, Lancet, 353, 2195, 10.1016/S0140-6736(98)12291-2 Rhee, 2003, Human immunodeficiency virus reverse transcriptase and protease sequence database, Nucleic Acids Res, 31, 298, 10.1093/nar/gkg100 Van Laethem, 2002, A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients, Antivir Ther, 7, 123, 10.1177/135965350200700206 Rousseau, 2001, Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy, J Acquir Immune Defic Syndr, 26, 36, 10.1097/00126334-200101010-00005 Beerenwinkel, 2002, Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype, Proc Natl Acad Sci U S A, 99, 8271, 10.1073/pnas.112177799 Altmann, 2009, Keeping models that predict response to antiretroviral therapy up-to-date: fusion of pure data-driven approaches with rules-based methods, Rev Antiviral Ther, 1, A92 Obermeier, 2012, HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge, Intervirology, 55, 102, 10.1159/000331999 Tang, 2012, The HIVdb system for HIV-1 genotypic resistance interpretation, Intervirology, 55, 98, 10.1159/000331998 Vercauteren, 2013, Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response, PLoS ONE, 8, pe61436, 10.1371/journal.pone.0061436 Eberle, 2012, The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2, Intervirology, 55, 128, 10.1159/000332009 Gibb, 2002, Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial), Antivir Ther, 7, 293, 10.1177/135965350200700410 Dam, 2009, Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss, PLoS Pathog, 5, pe1000345, 10.1371/journal.ppat.1000345 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2013. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf Vandamme, 2011, European recommendations for the clinical use of HIV drug resistance testing: 2011 update, AIDS Rev, 13, 77 Sing, 2007, Predicting HIV coreceptor usage on the basis of genetic and clinical covariates, Antivir Ther, 12, 1097, 10.1177/135965350701200709 Däumer, 2011, Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis, BMC Med Inform Decis Making, 11, 30, 10.1186/1472-6947-11-30 Thielen, 2012, Geno2pheno[454]: a web server for the prediction of HIV-1 coreceptor usage from next-generation sequencing data, Intervirology, 55, 113, 10.1159/000332002 Pfeifer, 2012, Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data, Bioinformatics, 28, pi589, 10.1093/bioinformatics/bts373 Vandekerckhove, 2011, European guidelines on the clinical management of HIV-1 tropism testing, Lancet Infect Dis, 11, 394, 10.1016/S1473-3099(10)70319-4 Wirden, 2011, Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia, J Antimicrob Chemother, 66, 709, 10.1093/jac/dkq544 Kabamba-Mukadi, 2010, HIV-1 proviral resistance mutations: usefulness in clinical practice, HIV Med, 11, 483 De Luca, 2003, Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance, J Infect Dis, 187, 1934, 10.1086/375355 Rosenbloom, 2012, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome, Nat Med, 18, 1378, 10.1038/nm.2892 Beerenwinkel, 2013, The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients, PLoS Comput Biol, 9, e1003203, 10.1371/journal.pcbi.1003203 Heider, 2013, Multilabel classification for exploiting cross-resistance information in HIV-1 drug resistance prediction, Bioinformatics, 29, 1946, 10.1093/bioinformatics/btt331 Altmann, 2009, Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database, J Infect Dis, 199, 999, 10.1086/597305 Rosen-Zvi, 2008, Selecting anti-HIV therapies based on a variety of genomic and clinical factors, Bioinformatics, 24, pi399, 10.1093/bioinformatics/btn141 Revell, 2011, The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool, AIDS, 25, 1855, 10.1097/QAD.0b013e328349a9c2 Bogojeska, 2012, History-alignment models for bias-aware prediction of virological response to HIV combination therapy, J Machine Learn Res, 22, 118 Saigo, 2011, Learning from past treatments and their outcome improves prediction of in vivo response to anti-HIV therapy, Stat Appl Genet Mol Biol, 10, pArticle6, 10.2202/1544-6115.1604 Bogojeska, 2011, History distribution matching method for predicting effectiveness of HIV combination therapies, 424 Moore, 2002, Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level, Science, 296, 1439, 10.1126/science.1069660 Ranasinghe, 2013, Association of HLA-DRB1-restricted CD4(+) T cell responses with HIV immune control, Nat Med, 19, 930, 10.1038/nm.3229 Däumer, 2010, Short communication: Selection of thymidine analogue resistance mutational patterns in children infected from a common HIV type 1 subtype G source, AIDS Res Hum Retroviruses, 26, 275, 10.1089/aid.2009.0233 Revell, 2013, Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings, J Antimicrob Chemother, 68, 1406, 10.1093/jac/dkt041 Prosperi, 2010, Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models, PLoS ONE, 5, e13753, 10.1371/journal.pone.0013753 Zazzi, 2011, Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study), HIV Med, 12, 211, 10.1111/j.1468-1293.2010.00871.x Larder, 2011, Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience, AIDS Patient Care STDS, 25, 29, 10.1089/apc.2010.0254 McGovern, 2012, Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial, J Acquir Immune Defic Syndr, 61, 279, 10.1097/QAI.0b013e31826249cf Swenson, 2011, Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients, J Infect Dis, 203, 237, 10.1093/infdis/jiq030 Simon, 2008, The use of genomics in clinical trial design, Clin Cancer Res, 14, 5984, 10.1158/1078-0432.CCR-07-4531 Freidlin, 2010, Randomized clinical trials with biomarkers: design issues, J Natl Cancer Inst, 102, 152, 10.1093/jnci/djp477 Mani, 2012, Novel clinical trial designs for the development of new antiretroviral agents, AIDS, 26, 899, 10.1097/QAD.0b013e3283519371 Chan-Tack, 2008, HIV clinical trial design for antiretroviral development: moving forward, AIDS, 22, 2419, 10.1097/QAD.0b013e32831692e6 Hsieh, 1998, A simple method of sample size calculation for linear and logistic regression, Stat Med, 17, 1623, 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S Efron, 2007, Size, power and false discovery rates, Ann Stat, 35, 1351, 10.1214/009053606000001460 Avidor, 2013, Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory, J Clin Microbiol, 51, 880, 10.1128/JCM.02652-12 Simen, 2009, Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes, J Infect Dis, 199, 693, 10.1086/596736 Bock, 2012, Managing drug resistance in cancer: lessons from HIV therapy, Nat Rev Cancer, 12, 494, 10.1038/nrc3297 Foeglein, 2007, Determination of HIV-1 coreceptor tropism in clinical practise, Eur J Med Res, 12, 473 Weber, 2013, Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism, J Clin Microbiol, 51, 1517, 10.1128/JCM.00092-13 Whitcomb, 2007, Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism, Antimicrob Agents Chemother, 51, 566, 10.1128/AAC.00853-06 Brumme, 2004, Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy, AIDS, 18, F1, 10.1097/00002030-200403050-00001 Lengauer, 2007, Bioinformatics prediction of HIV coreceptor usage, Nat Biotechnol, 25, 1407, 10.1038/nbt1371 Dybowski, 2010, Prediction of co-receptor usage of HIV-1 from genotype, PLoS Comput Biol, 6, e1000743, 10.1371/journal.pcbi.1000743 Bozek, 2013, Analysis of physicochemical and structural properties determining HIV-1 coreceptor usage, PLoS Comput Biol, 9, e1002977, 10.1371/journal.pcbi.1002977 Prosperi, 2010, Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping, Retrovirology, 7, 56, 10.1186/1742-4690-7-56 Palella, 1998, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators, N Engl J Med, 338, 853, 10.1056/NEJM199803263381301 Neff, 2003, ATS, CDC, and IDSA update recommendations on the treatment of tuberculosis, Am Fam Phys, 68, 1854